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OBJECTIVES The study evaluates the effect of atrial natriuretic peptide (ANP) compared with nitroglycerin
(GTN) on left ventricular (LV) remodeling after first anterior acute myocardial infarction
(AMI).
BACKGROUND Compared with GTN, ANP suppresses the renin-angiotensin-aldosterone system and
endothelin-1 (ET-1), which stimulate LV remodeling.
METHODS Sixty patients with a first anterior AMI were randomly divided into the ANP (n 5 30) or
GTN (n 5 30) groups after direct percutaneous transluminal coronary angioplasty. We
evaluated LV ejection fraction (LVEF), end-diastolic volume index (LVEDVI) and end-
systolic volume index (LVESVI) at the acute phase and after one month. We also measured
neurohumoral factors during study drug infusion.
RESULTS There was no difference in the baseline characteristics or LVEF (46.9 6 1.0 vs. 46.8 6 1.3%)
between the two groups. Although there was no difference in hemodynamics during the
infusion periods, the LVEF was significantly improved after one month compared with the
baseline value in both groups, but it was improved more in the ANP group than in the GTN
group (54.6 6 1.1%, 50.8 6 1.3%, p , 0.05). Left ventricular enlargement was prevented in
the ANP group (LVEDVI, 85.8 6 3.1 ml/m2 to 87.3 6 2.7 ml/m2; p 5 ns, LVESVI, 45.6 6
1.8 ml/m2 to 41.0 6 2.1 ml/m2, p , 0.05) but not in the GTN group (LVEDVI, 86.2 6 4.1
to 100.2 6 3.7, p , 0.01; LVESVI, 46.3 6 2.8 ml/m2 to 51.1 6 3.0 ml/m2, p 5 ns). During
the infusion, ANP suppressed plasma levels of aldosterone, angiotensin II and ET-1
compared with GTN.
CONCLUSIONS These findings indicate that in patients with a first anterior AMI, an ANP infusion can
prevent LV remodeling better than can GTN, and effectively suppresses aldosterone,
angiotensin II and ET-1. (J Am Coll Cardiol 2001;37:1820–6) © 2001 by the American
College of Cardiology
Previous studies demonstrated that left ventricular (LV)
remodeling was one of the major factors for determining
long-term survival after an acute myocardial infarction
(AMI) (1). Therefore, it is important to prevent LV
remodeling to get a better clinical outcome and prognosis in
patients with AMI. In the acute phase of AMI, nitroglyc-
erin (GTN) has been reported to have a favorable effect in
preventing LV remodeling (2). However, GTN may stim-
ulate the renin-angiotensin-aldosterone system despite its
beneficial hemodynamic effect (3). In contrast, atrial natri-
uretic peptide (ANP) has been demonstrated to suppress the
renin-angiotensin-aldosterone system and endothelin-1
(ET-1) (4–8), which stimulate LV remodeling.
Recently, endogenous cardiac natriuretic peptides were
reported to have a direct effect in inhibiting myocardial
hypertrophy through the biological receptors on the myo-
cardium (9). Moreover, the secretion of ANP during the
acute phase of AMI may be insufficient relative to the
chronic phase (10). If so, augmentation of the cardiac
natriuretic peptide system, such as by exogenous adminis-
tration of ANP, may be a useful supplementary therapy for
preventing LV remodeling because of the cardioprotective
actions of ANP (9,11), such as suppression of the renin-
angiotensin-aldosterone system (4–8). Thus, we believe
that the intravenous administration of ANP in patients with
AMI may prevent LV dilation and remodeling after AMI.
METHODS
Study population. From December 1997 through August
2000, 65 patients admitted to the coronary care units of our
institutions with a first anterior AMI who presented with
Thrombolysis In Myocardial Infarction (TIMI) grade 0 or 1
flow at initial coronary angiography were considered for the
study. Admission criteria included prolonged chest pain
(.30 min), an electrocardiographic ST segment elevation
.2 mV in two or more adjacent precordial leads, successful
From the First Department of Internal Medicine, Shiga University of Medical
Science, Tsukinowa, Seta, Otsu, Japan. This study was partly supported by a Japanese
Grant-in-Aid for Scientific Research.
Manuscript received November 1, 2000; revised manuscript received January 30,
2001, accepted February 15, 2001.
Journal of the American College of Cardiology Vol. 37, No. 7, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01233-5
reperfusion therapy within 24 h of the onset of chest pain
documented by coronary angiography and more than a
threefold increase in serum creatine phosphokinase levels.
Patients were excluded for the following reasons: age .80
years; cardiogenic shock or hypotension, defined as systolic
blood pressure ,90 mm Hg; prior myocardial infarction;
treatment with an oral angiotensin-converting enzyme in-
hibitor within the previous two weeks; LV end-diastolic
pressure .35 mm Hg or significant stenosis of the infarct-
nonrelated coronary artery. All patients gave informed
consent, and the study was approved by the Committee on
Human Investigation at our institution.
Study design and protocol. This was a prospective ran-
domized study. Sixty-five patients were randomly divided
into two groups, ANP or GTN. All patients underwent
cardiac catheterization with the femoral approach after an
injection of 100 U/kg of heparin. The infarct-related artery
was visualized in five views with contrast injections, and
patency was determined according to the classification of
the TIMI trial. Patients who had persistent occlusion of the
infarct-related vessel (TIMI grade 0 or 1) underwent
percutaneous transluminal coronary angioplasty following
standard techniques. After revascularization (TIMI grade
3), biplane left ventriculography was performed. After
angioplasty, all patients received oral aspirin and/or ticlopi-
dine. If required, oral calcium antagonists, beta-adrenergic
blocking agents and/or diuretics were added and continued.
However, angiotensin-converting enzyme inhibitors and
nitrates were inhibited while patients were undergoing
continuous administration of ANP or GTN infusion.
Just after patients’ arriving in the coronary care unit with
hemodynamic stability assured (two measurements at
15-min interval), ANP or GTN infusion was started at
0.025 mg/kg/min (ANP case) or 0.4 mg/kg/min (GTN
case). Continuous measurements of hemodynamic parame-
ters such as arterial blood pressure, heart rate, cardiac output
and pulmonary artery blood pressure were obtained. If the
systolic arterial blood pressure was high (.150 mm Hg) or
low (,90 mm Hg) within 30 min of starting the infusion,
doses of ANP and GTN were changed to maintain constant
blood pressure, then ANP or GTN was continuously
infused for .24 h. After intravenous ANP or GTN was
stopped, all patients were administrated oral angiotensin-
converting enzyme inhibitor (enalapril). Repeat cardiac
catheterization was performed one month after the initial
catheterization to determine culprit artery patency and LV
function. Patients with significant restenosis of the culprit
lesion were excluded from the study.
Hemodynamic measurements. Left ventriculography per-
formed by contrast medium was analyzed for LVEF and LV
volume by cardiologists who were unaware of the patients’
data at acute phase and after one month. Left ventricular
ejection fraction was calculated by the area-length method.
The hemodynamic measurements of pulmonary arterial
blood pressure, pulmonary capillary wedge pressure, right
atrial pressure, cardiac output (thermodilution method)
arterial blood pressure and heart rate were made before
administering the ANP or GTN infusion, 1 h after starting
the infusion and just before stopping the infusion.
Neurohumoral measurements. Blood for the measure-
ments of plasma levels of active renin, angiotensin II (Ang
II), aldosterone (ALD), ET-1, norepinephrine, ANP, brain
natriuretic peptide (BNP) and cyclic guanosine monophos-
phate (cGMP) was obtained just before intravenous ANP or
GTN treatment, 1 h after starting the treatment and just
before stopping the infusion. Plasma level of ANP and BNP
was measured with a specific immunoradiometric assay
using commercial kits (Shionogi, Osaka, Japan) as previ-
ously reported (12). The plasma ET-1 level was determined
using an antibody directed against synthetic ET-1 (Penin-
sula Laboratories, Inc., Belmont, California) and 125I ET-1
(Amersham Japan, Tokyo, Japan) as previously reported
(13). Plasma cGMP levels were measured by radioimmu-
noassay with a commercial kit as previously reported (12).
Plasma norepinephrine concentrations were measured by
high-performance liquid chromatography. Plasma Ang II
levels were measured by a radioimmunoassay using a specific
antibody directed against synthetic Ang II (Special Research
Laboratory, Tokyo, Japan) as previously reported (13).
Plasma active renin and ALD levels were measured using
commercial radioimmunoassay kits.
Statistical analysis. All results are expressed as mean 6
SEM. Univariate analyses were performed using Student t
test for continuous variables. Categorical data were com-
pared against a chi-squared distribution. In patients who
underwent repeat hemodynamic, neurohumoral and LV
functional assessment, changes from baseline were evaluated
within each treatment group with analysis of variance by
Scheffe´ F test and between the ANP and GTN groups by
two-way analysis of variance. A p-value ,0.05 was regarded
as significant.
RESULTS
Clinical characteristics (Table 1). Sixty-five consecutive
patients who met entry criteria were enrolled. Thirty-three
patients were randomized to GTN treatment and 32 to
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ANP treatment. In the GTN group, one patient had a
cerebral hemorrhage, one died from lethal arrhythmia, and
one was excluded because of restenosis in the culprit lesion.
In the ANP group, one patient died eight days after
congestive heart failure and one was excluded because of
restenosis. Therefore, 60 of 65 patients enrolled in the trial
completed the entire protocol. The average infusion dose
was 0.028 6 0.002 mg/kg/min in the ANP group (n 5 30)
and 0.48 6 0.04 mg/kg/min in the GTN group (n 5 30),
respectively. There was no difference of baseline character-
istics, including maximum levels of creatine phosphokinase
(CK) and duration of infusion time, between the ANP
group and the GTN group (Table 1). There was also no
difference of therapy including the doses of enalapril be-
tween the two groups.
Hemodynamic parameters (Table 2). There was no dif-
ference in hemodynamic parameters at baseline between the
two groups. Moreover, there were no significant differences
between the two groups in these hemodynamic parameters
after 1 h and before stopping the infusion of GTN or ANP.
Serial changes of mean arterial blood pressure, pulmonary
capillary wedge pressure and mean pulmonary arterial pres-
sure, which were significantly decreased after 1 h and
decreased versus baseline values until the end of infusion,
were similar in both groups.
LV volume and function (Fig. 1, Table 3). There was no
difference in LVEF at baseline, and it was significantly
increased in both groups after one month as shown in
Figure 1 and Table 3, but the increase in LVEF with ANP
was greater than with GTN. The change in LVEF of the
ANP group was significantly higher than that of the GTN
group (7.70 6 1.3%, 4.08 6 1.1%, p , 0.05), and LVEF at
one month in the ANP group was significantly higher than
that in the GTN group. There was no difference in
LVEDVI at baseline. However, in the GTN group the
LVEDVI was significantly increased whereas LVEDVI did
Table 1. Baseline Characteristics
ANP (n 5 30) GTN (n 5 30)
p
Value
Age (yrs) 60.9 6 1.9 59.4 6 2.1 n.s.
Gender (male/female) 19/11 21/9 n.s.
Symptom onset-reflow
time (h)
5.2 6 0.9 5.1 6 0.8 n.s.
Max CK (IU/ml) 3322 6 388 3518 6 332 n.s.
LV function and volumes
LVEF (%) 46.9 6 1.0 46.7 6 1.3 n.s.
LVEDVI (ml/m2) 85.8 6 3.1 86.2 6 4.1 n.s.
LVESVI (ml/m2) 45.6 6 1.8 46.3 6 2.8 n.s.
Collateral (grade .2) 7 4 n.s.
Risk factors
Smoking 15 18 n.s.
Hypertension 8 9 n.s.
Hyperlipidemia 11 13 n.s.
Diabetes mellitus 14 14 n.s.
In-hospital therapy
Catecholamine 5 7 n.s.
IABP 2 3 n.s.
Oral nitrates 28 27 n.s.
Ca antagonists 7 5 n.s.
Diuretics 3 4 n.s.
Beta-blockers 7 8 n.s.
Enalapril dose (mg) 9.1 6 0.4 10.1 6 0.4 n.s.
Infusion time of study
drug (h)
61.5 6 5.6 64.0 6 4.9 n.s.
Study drug dose
(mg/kg/min)
0.028 6 0.002 0.476 6 0.04 —
ANP 5 atrial natriuretic peptide; CK 5 creatine phosphokinase; GTN 5 nitroglyc-
erin; IABP 5 intra-aortic balloon pumping; LVEDVI 5 left ventricular end-diastolic
volume index; LVEF 5 left ventricular ejection fraction; LVESVI 5 left ventricular
end-systolic volume index; n.s. 5 not stated.
Table 2. Hemodynamic Changes During the Study Drug Infusion
Baseline 1 h Before Stop
p Value (analysis of variance)
Group Time Interaction
HR (beats/min)
ANP 79.2 6 2.4 78.5 6 2.4 75.7 6 1.9
n.s. n.s. n.s.
GTN 78.2 6 2.1 80.4 6 2.0 79.1 6 2.3
MBP (mm Hg)
ANP 93.0 6 1.9 87.8 6 2.0* 85.0 6 1.0†
n.s. ,0.0001 n.s.
GTN 91.3 6 2.0 87.2 6 1.9‡ 86.1 6 1.3*
CI (l/min/m2)
ANP 2.82 6 0.17 2.80 6 0.15 2.55 6 0.09‡
n.s. 0.003 n.s.
GTN 2.75 6 0.10 2.74 6 0.08 2.66 6 0.07
PCWP (mm Hg)
ANP 16.0 6 0.8 13.5 6 0.7§ 11.5 6 0.7†
n.s. ,0.0001 n.s.
GTN 16.5 6 0.8 14.1 6 1.0* 13.2 6 0.8§
MPA (mm Hg)
ANP 19.8 6 0.8 16.2 6 0.7† 13.7 6 0.5†
n.s. ,0.0001 n.s.
GTN 20.0 6 1.2 17.0 6 1.1* 14.4 6 0.7†
RA (mm Hg)
ANP 6.3 6 0.4 5.6 6 0.4 5.6 6 0.4
n.s. ,0.0001 n.s.
GTN 6.8 6 0.5 6.2 6 0.5 5.5 6 0.4*
*p , 0.01, †p , 0.0001, ‡p , 0.05, §p , 0.001: difference between baseline and 1 h or before stop within each group.
ANP 5 atrial natriuretic peptide; CI 5 cardiac index; GTN 5 nitroglycerin; HR 5 heart rate; MBP 5 mean arterial blood pressure; MPA 5 mean pulmonary arterial
pressure; n.s. 5 not stated; PCWP 5 pulmonary capillary wedge pressure; RA 5 right atrial pressure.
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not change in the ANP group. Atrial natriuretic peptide but
not GTN prevented the increase in LVEDVI. There was no
difference of LVESVI at baseline, and LVESVI tended to
increase in the GTN group but was significantly decreased
in the ANP group. The changes in LVEDVI (1.50 6
3.5 ml/m2 vs. 14.0 6 4.7 ml/m2: p , 0.05) and LVESVI
(24.57 6 2.0 ml/m2 vs. 4.87 6 2.8 ml/m2: p , 0.01) were
significantly smaller in the ANP group than in the GTN
group.
Comparison of plasma neurohumoral factors during the
infusion of GTN or ANP. At baseline, there were no
significant differences between the two groups in plasma
levels of ANP, BNP and cGMP (Table 4). Plasma levels of
ANP and cGMP were increased after 1 h and increased
compared with the baseline value during infusion in the
ANP group but not in the GTN group. There was no
difference of plasma ANP levels at 1 h and before stopping,
but the plasma cGMP level was significantly lower before
stopping compared with the value after 1 h.
At baseline, there was no significant difference in plasma
levels of norepinephrine, active renin, Ang II, ALD or
ET-1 between the two groups (Fig. 2, Table 4). After 1 h
of infusion, the plasma ALD level was significantly sup-
pressed in the ANP group. Plasma levels of Ang II, ALD
and ET-1 were significantly suppressed in the ANP group
compared with the GTN group. On the other hand, plasma
norepinephrine and active renin levels were not different
between the two groups during the infusion periods.
DISCUSSION
Our findings demonstrate for the first time that treatment with
an ANP infusion started immediately from the onset after
direct percutaneous transluminal coronary angioplasty can
prevent LV dilation more effectively than GTN and better
improve the LVEF in patients with a first anterior AMI.
Although there was no difference in the baseline charac-
teristics, including the maximum level of CK and LVEF,
and there was no difference in hemodynamics between the
two groups during the infusion periods, LVEF and
LVEDVI were more improved in the ANP group than the
GTN group. Moreover, plasma levels of ALD, Ang II and
ET-1 were suppressed in the ANP group compared with
the GTN group. These findings indicate that treatment
with an ANP infusion can prevent LV remodeling in
patients with a first anterior AMI compared with GTN
partly due to the suppression of ALD, Ang II and ET-1.
Dose setting of ANP or GTN. We chose an ANP starting
dose of 0.025 mg/kg/min because in our preliminary study,
a reduction of the preload and blood pressure had a mild
acute effect; the more preload and afterload reduction the
more varoreflex activation, which diminished the beneficial
effects of suppressing sympathetic nerve activity and the
renin-angiotensin-aldosterone system. Then, we chose the
starting dose of GTN at a comparative dose to decrease the
preload. As a result, the plasma level of ANP increased
within the pathophysiologic range that is observed in severe
heart failure (12), and the acute effects of ANP and GTN
on hemodynamic parameters were the same.
Figure 1. Changes in the ejection fraction (EF), left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index
(LVESVI) in the two randomized treatment groups from baseline to one month after. P(ANOVA) indicates the p value for time-group interaction. The
white bars indicate the ANP group and the black bars the GTN group. *p , 0.001: difference between baseline and one-month values (within each group),
†p , 0.05, #p , 0.01.
Table 3. Changes in LVEF, EDVI and ESVI from Baseline to One Month
ANP (n 5 30) GTN (n 5 30) p Value (analysis of variance)
Baseline One Month Baseline One Month Group Time Interaction
LVEF (%) 46.9 6 1.0 54.6 6 1.1* 46.8 6 1.3 50.8 6 1.3† n.s. ,0.0001 0.034
LVEDVI (ml/m2) 85.8 6 3.1 87.3 6 2.7 86.2 6 4.1 100.2 6 3.7† n.s. 0.011 0.037
LVESVI (ml/m2) 45.6 6 1.8 41.0 6 2.1‡ 46.3 6 2.8 51.1 6 3.0 n.s. n.s. 0.009
*p , 0.001, †p , 0.01, ‡p , 0.05: difference between baseline and one-month values (within each group).
ANP 5 atrial natriuretic peptide; EDVI 5 end-diastolic volume index; ESVI 5 end-systolic volume index; GTN 5 nitroglycerin; LVEDVI 5 left ventricular end-diastolic
volume index; LVEF 5 left ventricular ejection fraction; LVESVI 5 left ventricular end-systolic volume index; n.s. 5 not stated.
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Possible mechanism of beneficial effects of ANP on LV
remodeling. Because ANP has an inhibitory effect on
sympathetic nerve activity (14), we hypothesized that the
indexes of sympathetic nerve activity were different during
infusion periods between the two groups. However, there
was no difference of plasma norepinephrine or heart rates,
which was probably because of the relatively small dose of
ANP or GTN and the slight reduction of the mean arterial
blood pressure in this study.
In our study, the plasma levels of ALD, Ang II and ET-1
were significantly suppressed in the ANP group compared
with the GTN group. Especially, the plasma ALD level was
significantly decreased after 1 h and suppressed during the
infusion of ANP. Aldosterone levels have been found to be
increased in patients with AMI, and aldosterone shows both
myocardial and renal effects that may have profound impli-
cations for LV remodeling (15,16). We recently reported
that plasma ALD is extracted through the heart in patients
with heart failure, and that a positive correlation exists
between the transcardiac gradient of ALD, which correlates
with plasma ALD level, and LVEDVI. We also demon-
strated that transcardiac ALD extraction is an important
modulator of LV remodeling (17). In this earlier study, 60%
of the population consisted of old myocardial infarctions.
Therefore, the significant suppression of plasma ALD by
ANP compared with that by GTN may have passively
prevented LV remodeling in the present study. In rat
models, after myocardial infarction, tissue-specific activa-
tion of myocardial ALD synthesis was reported (18). Aldo-
sterone has been shown to stimulate cardiac collagen syn-
thesis and fibroblast proliferation via activation of local
mineralocorticoid receptors (19). Atrial natriuretic peptide
Figure 2. Effects of intravenous atrial natriuretic peptide (ANP) and nitroglycerin (GTN) on norepinephrine (NE), plasma active renin concentration
(PARC), angiotensin II (Ang II), aldosterone (ALD) and endothelin-1 (ET-1). P(ANOVA) indicates the p value for time-group interaction. White bars
indicate ANP group and black bars the GTN group. Baseline and 1 H indicate just before and after 1 H starting ANP or GTN. Before stop indicates
just before stopping ANP or GTN. †p , 0.05, #p , 0.01, *p , 0.001, §p , 0.0001: difference between baseline and before stop values (within each group).
Table 4. Changes in the Neurohumoral Factors During the Study Drug Infusion
ANP (n 5 30) GTN (n 5 30) p Value (analysis of variance)
Baseline 1 h Before Stop Baseline 1 h Before Stop Group Time Interaction
ANP (pg/ml) 60.3 6 7.8 473 6 59* 483 6 57* 70 6 11 53 6 8 90 6 31 ,0.0001 ,0.0001 ,0.0001
BNP (pg/ml) 156 6 35 215 6 41† 209 6 35 140 6 30 161 6 38 219 6 41† n.s. 0.012 n.s.
cGMP (pmol/l) 6.7 6 0.7 21.2 6 1.6* 14.3 6 1.0* 7.5 6 0.7 6.0 6 0.7 6.5 6 0.8 ,0.0001 ,0.0001 ,0.0001
NE (pg/ml) 456 6 40 480 6 40 431 6 39 575 6 118 576 6 82 465 6 48 n.s. n.s. n.s.
PARC (pg/ml) 37.9 6 13.0 35.0 6 12.8 30.0 6 7.3 38.6 6 12.1 43.1 6 17.9 42.9 6 10.6 n.s. n.s. n.s.
Ang II (pg/ml) 10.4 6 2.0 9.6 6 1.7 9.0 6 0.9 7.5 6 0.6 12.4 6 3.8 17.9 6 3.2‡ n.s. 0.025 0.002
ALD (pg/ml) 67.6 6 9.3 44.8 6 4.6† 37.9 6 7.5‡ 65.5 6 8.9 78.4 6 13.5 67.1 6 8.4 n.s. 0.048 0.012
ET-1 (pg/ml) 4.37 6 0.28 4.06 6 0.32 2.38 6 0.13* 4.23 6 0.34 4.84 6 0.44 3.34 6 0.27 n.s. ,0.0001 0.049
*p , 0.0001, †p , 0.05, ‡p , 0.01 vs. baseline values (within each group).
ALD 5 aldosterone; Ang II 5 angiotensin II; ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; cGMP 5 cyclic guanosine monophosphate; ET-1 5
endothelin-1; NE 5 norepinephrine; n.s. 5 not stated; PARC 5 plasma active renin concentration.
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directly inhibits ALD secretion (7) and attenuates the
stimulatory effect of Ang II on ALD release (6). The great
success of spironolactone for the treatment of heart failure
suggests the important role of ALD on the progression of
LV remodeling and LV dysfunction (20). Therefore, the
beneficial effect of ANP on the LV remodeling is partly due
to the suppression of the plasma ALD level.
The significant reductions of plasma Ang II and ET-1 in
the ANP group compared with the GTN group may also
have beneficial effects on LV remodeling because of the
important role of myocardial hypertrophy and the LV
remodeling process via a direct effect and/or interaction
(21,22). The previous study demonstrated that Ang II and
ALD each play a role in promoting structural remodeling of
the myocardium. Although fibrosis was seen in ventricles in
each model, combined elevation in the circulating Ang II
and ALD more rapidly induced fibrous tissue response than
elevation of plasma ALD (23). In the present study, ANP
significantly suppressed plasma levels of both Ang II and
ALD, so this effect of ANP may play a role in preventing
LV remodeling in the ANP group. Exposure of myocardial
fibroblasts to Ang II in a cell culture produces a mitogenic
effect, apparently triggered by immediate early gene expres-
sion, with increased proliferation and collagen synthesis
(24). Atrial natriuretic peptide inhibits Ang II-stimulated
proliferation of cardiac fibroblast (25).
Regarding ET-1 in patients with AMI, ET-1 levels
increase and their elevation is associated with infarct size
and a poor prognosis (26). In infarcted rat models, ET-1
promotes LV fibrosis, and remodeling and ventricular re-
modeling were prevented and cardiac function improved by
blocking the endothelin receptors (27,28). Atrial natriuretic
peptide has been shown to inhibit the biosynthesis and
release of ET-1 (8). We demonstrated that elevated circu-
lating ET-1 is extracted across the failing heart in patients
with heart failure, of which 73% had old myocardial
infarction, and that there is positive correlation between the
transcardiac extraction of plasma ET-1 and the LVEDVI.
The transcardiac gradient of plasma ET-1 correlated with
the plasma level (29). Taken together, therefore, the effect
of ANP in decreasing plasma ET-1 may also have contrib-
uted to the prevention of ventricular remodeling in the
present study.
Finally, ANP has been demonstrated to play a role in the
regulation of cardiac myocyte growth because endogenous
ANP inhibits myocyte hypertrophy (9) and cardiac fibro-
blast collagen synthesis (11) through a cGMP-dependent
process. Therefore, exogenous ANP may have direct effect
on LV remodeling through biological receptors on the
myocardium.
Study limitations. In this study, patients with high LV
end-diastolic pressure (.35 mm Hg) were excluded for
ethical reasons to avoid performing left ventriculography at
the acute phase. Therefore, patients with very severe and
large infarctions may have been excluded from this study
population. Pfeffer et al. (30) reported that treatment effects
appeared to be highest in patients with intermediate-sized
infarcts, and also demonstrated that the greatest treatment
benefit of captopril occurred in medium-sized infarcts in rat
infarct models after long-term follow-up. In the Captopril
and Thrombolysis Study, captopril was effective in prevent-
ing LV remodeling in those with small and medium infarcts
(31). In the present study, it may have influenced the results
of ANP because those with very severe and large infarcts
were excluded.
Conclusions. The findings of the present study demon-
strate that treatment with an ANP infusion started imme-
diately after direct PTCA can prevent LV dilation and
improve LVEF in patients with a first anterior AMI. The
mechanism of the beneficial effects remains uncertain, but
the effects of ANP may be partly due to the suppression of
plasma levels of ALD, Ang II and ET-1.
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